MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis

Oncotarget

Volumn 6, Issue 1, 2015, Pages 471-483

  Katia, Danza ^a   Simona, De Summa ^a   Rosamaria, Pinto ^a   Brunella, Pilato ^a   Orazio, Palumbo ^a   Giuseppe, Merla ^b   Gianni, Simone ^a   Tommasi, Stefania ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Angiogenesis; BRCA; Familial breast cancer; miR 573; miR 578

Indexed keywords

ANGIOPOIETIN 2; BRCA1 PROTEIN; BRCA2 PROTEIN; FOCAL ADHESION KINASE; HYPOXIA INDUCIBLE FACTOR 1; MICRORNA; MICRORNA 573; MICRORNA 578; UNCLASSIFIED DRUG; VASCULOTROPIN A; MIRN573 MICRORNA, HUMAN; TRANSCRIPTOME;

ANGIOPOIETIN 2 GENE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; FAMILIAL CANCER; FOCAL ADHESION KINASE GENE; GENE EXPRESSION; GENE MUTATION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA INDUCIBLE FACTOR 1 GENE; MCF 7 CELL LINE; MICROARRAY ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84921419238     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Longatto Filho A, Lopes JM and Schmitt FC. Angiogenesis and breast cancer. Journal of oncology. 2010; 2010.
2. Yang W, Lee DY and Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. International journal of physiology, pathophysiology and pharmacology. 2011; 3(2):140-155.
3. Lages E, Ipas H, Guttin A, Nesr H, Berger F and Issartel JP. MicroRNAs: molecular features and role in cancer. Frontiers in bioscience. 2012; 17:2508-2540.
4. Gotte M. MicroRNAs in breast cancer pathogenesis. Minerva ginecologica. 2010; 62(6):559-571.
5. Palacios J, Robles-Frias MJ, Castilla MA, Lopez-Garcia MA and Benitez J. The molecular pathology of hereditary breast cancer. Pathobiology. 2008; 75(2):85-94.
6. Chang S and Sharan SK. The role of epigenetic transcriptional regulation in BRCA1-mediated tumor suppression. Transcription. 2013; 4(1):24-28.
7. Pinto R, Pilato B, Ottini L, Lambo R, Simone G, Paradiso A and Tommasi S. Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol. 2013; 228(6):1264-1269.
8. Tanic M, Yanowsky K, Rodriguez-Antona C, Andres R, Marquez-Rodas I, Osorio A, Benitez J and Martinez-Delgado B. Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One. 2012; 7(6):e38847.
9. Tanic M, Andres E, Rodriguez-Pinilla SM, Marquez-Rodas I, Cebollero-Presmanes M, Fernandez V, Osorio A, Benitez J and Martinez-Delgado B. MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. Br J Cancer. 2013; 109(10):2724-2734.
10. Murria Estal R, Palanca Suela S, de Juan Jimenez I, Egoavil Rojas C, Garcia-Casado Z, Juan Fita MJ, Sanchez Heras AB, Segura Huerta A, Chirivella Gonzalez I, Sanchez-Izquierdo D, Llop Garcia M, Barragan Gonzalez E and Bolufer Gilabert P. MicroRNA signatures in hereditary breast cancer. Breast Cancer Res Treat. 2013; 142(1):19-30.
11. Tanic M, Yanowski K, Gomez-Lopez G, Socorro Rodriguez-Pinilla M, Marquez-Rodas I, Osorio A, Pisano DG, Martinez-Delgado B and Benitez J. MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffinembedded formalin-fixed breast tumors. Int J Cancer. 2014.
12. Chang S and Sharan SK. BRCA1 and microRNAs: emerging networks and potential therapeutic targets. Mol Cells. 2012; 34(5):425-432.
13. Vassilopoulos A, Deng CX and Chavakis T. Crosstalk between the DNA damage response, histone modifications and neovascularisation. Int J Biochem Cell Biol. 2010; 42(2):193-197.
14. Kawai H, Li H, Chun P, Avraham S and Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 2002; 21(50):7730-7739.
15. Furuta S, Wang JM, Wei S, Jeng YM, Jiang X, Gu B, Chen PL, Lee EY and Lee WH. Removal of BRCA1/ CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell. 2006; 10(1):13-24.
16. Grillo J, DelloRusso C, Lynch RC, Folkman J and Zaslavsky A. Regulation of the angiogenesis inhibitor thrombospondin-1 by the breast cancer susceptibility gene-1 (BRCA1). Breast J. 2011; 17(4):434-435.
17. Danza K, Pilato B, Lacalamita R, Addati T, Giotta F, Bruno A, Paradiso A and Tommasi S. Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer. Eur J Hum Genet. 2013; 21(8):824-830.
18. Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A and Mangia A. VEGF, HIF-1alpha expression and MVD as an angiogenic network in familial breast cancer. PLoS One. 2013; 8(1):e53070.
19. Yan M, Rayoo M, Takano EA and Fox SB. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer. 2009; 101(7):1168-1174.
20. van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG and van der Wall E. HIF-1alpha overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS One. 2013; 8(2):e56055.
21. van der Groep P, Bouter A, Menko FH, van der Wall E and van Diest PJ. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat. 2008; 111(3):475-480.
22. Munoz-Chapuli R. Evolution of angiogenesis. Int J Dev Biol. 2011; 55(4-5):345-351.
23. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4):271-282.
24. Lechertier T and Hodivala-Dilke K. Focal adhesion kinase and tumour angiogenesis. J Pathol. 2012; 226(2):404-412.
25. Coene ED, Gadelha C, White N, Malhas A, Thomas B, Shaw M and Vaux DJ. A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol. 2011; 192(3):497-512.
26. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, Chang J, Simkins S and Xu L. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res. 2000; 6(6):2417-2423.
27. Watermann DO, Gabriel B, Jager M, Orlowska-Volk M, Hasenburg A, zur Hausen A, Gitsch G and Stickeler E. Specific induction of pp125 focal adhesion kinase in human breast cancer. Br J Cancer. 2005; 93(6):694-698.
28. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF and Giancotti FG. Ras-and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009; 119(2):252-266.
29. Yom CK, Noh DY, Kim WH and Kim HS. Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res Treat. 2011; 128(3):647-655.
30. Alexopoulou AN, Ho-Yen CM, Papalazarou V, Elia G, Jones JL and Hodivala-Dilke K. Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer. BMC Cancer. 2014; 14:237.
31. Wang HF, Chen H, Ma MW, Wang JA, Tang TT, Ni LS, Yu JL, Li YZ and Bai BX. miR-573 regulates melanoma progression by targeting the melanoma cell adhesion molecule. Oncol Rep. 2013; 30(1):520-526.
32. Fox SB, Generali DG and Harris AL. Breast tumour angiogenesis. Breast Cancer Research. 2007; 9(6).
33. De S, Razorenova O, McCabe NP, O'Toole T, Qin J and Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A. 2005; 102(21):7589-7594.
34. Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, Cheresh DA and Schlaepfer DD. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene. 2006; 25(44):5969-5984.
35. Liu L, Ning X, Sun L, Shi Y, Han S, Guo C, Chen Y, Sun S, Yin F, Wu K and Fan D. Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol Cell Biochem. 2007; 303(1-2):151-160.
36. Seko Y, Takahashi N, Sabe H, Tobe K, Kadowaki T and Nagai R. Hypoxia induces activation and subcellular translocation of focal adhesion kinase (p125(FAK)) in cultured rat cardiac myocytes. Biochem Biophys Res Commun. 1999; 262(1):290-296.
37. Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, Kienast Y, Vettel C, Loos EK, Kutschera S, Bartels S, Appak S, Besemfelder E, Terhardt D, Chavakis E, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest. 2012; 122(6):1991-2005.
38. Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D, Mangia A and Paradiso A. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res. 2005; 578(1-2):395-405.
39. Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, Digennaro M, Schittulli F, Lacalamita R and Paradiso A. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res. 2008; 644(1-2):64-70.